# Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer

> **NCT00408902** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 10 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma
- Recurrent Renal Cell Cancer
- Stage IV Renal Cell Cancer

## Interventions

- **DRUG:** tandutinib
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00408902
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2008-10
- **Final completion:** 2008-12
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2017-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00408902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00408902, "Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00408902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*